The Pharma Consortium

The DIAN-TU Pharma Consortium, formed in 2011, is a worldwide collaboration of the DIAN-TU with pharmaceutical companies and research institutions to advise on the design and implementation of DIAN-TU therapeutic trials. DIAN-TU Pharma Consortium funding supported the formation of the DIAN-TU, including establishment of the DIAN Expanded Registry and ancillary studies to help inform on trial design. The DIAN-TU Pharma Consortium meets regularly to provide ongoing expertise for pre-competitive trial design, support ancillary studies and nominate therapies for the DIAN-TU trials.

With the support from the DIAN-TU Pharma Consortium, the DIAN-TU has and will continue to design effective, safe and efficient trials to provide advancement of treatments, scientific understanding and improvements in the approach to Alzheimer’s disease drug development.

Members

Abbvie

Biogen

Eisai

Janssen

Lilly/Avid

Roche/Genentech

We gratefully acknowledge the following founding former members of the DIAN Pharmaceutical Consortium: Elan, Forum Pharmaceuticals, Mithridion, Novartis, Amgen, AstraZeneca, Pfizer and Sanofi.